DK1234043T3 - Konstruktion for afgivelse af terapeutiske midler til neuroceller - Google Patents
Konstruktion for afgivelse af terapeutiske midler til neurocellerInfo
- Publication number
- DK1234043T3 DK1234043T3 DK00979809T DK00979809T DK1234043T3 DK 1234043 T3 DK1234043 T3 DK 1234043T3 DK 00979809 T DK00979809 T DK 00979809T DK 00979809 T DK00979809 T DK 00979809T DK 1234043 T3 DK1234043 T3 DK 1234043T3
- Authority
- DK
- Denmark
- Prior art keywords
- delivery
- neurocells
- construction
- therapeutic agents
- domain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9928530.6A GB9928530D0 (en) | 1999-12-02 | 1999-12-02 | Constructs for delivery of therapeutic agents to neuronal cells |
GB0008658A GB0008658D0 (en) | 2000-04-07 | 2000-04-07 | Constructs for delivery of therapeutic agents to neuronal cells |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1234043T3 true DK1234043T3 (da) | 2004-07-19 |
Family
ID=26244065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00979809T DK1234043T3 (da) | 1999-12-02 | 2000-12-04 | Konstruktion for afgivelse af terapeutiske midler til neuroceller |
Country Status (11)
Country | Link |
---|---|
US (2) | US20090269361A1 (da) |
EP (1) | EP1234043B1 (da) |
JP (1) | JP4991073B2 (da) |
AT (1) | ATE261494T1 (da) |
AU (1) | AU768529B2 (da) |
CA (1) | CA2392202C (da) |
DE (1) | DE60008915T2 (da) |
DK (1) | DK1234043T3 (da) |
ES (1) | ES2216996T3 (da) |
PT (1) | PT1234043E (da) |
WO (1) | WO2001058936A2 (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192596B2 (en) | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7923015B2 (en) * | 1997-08-14 | 2011-04-12 | Institut Pasteur | Methods for direct visualization of active synapses |
US7923216B2 (en) | 1997-08-14 | 2011-04-12 | Institut Pasteur | In vivo modulation of neuronal transport |
GB0216865D0 (en) * | 2002-07-19 | 2002-08-28 | Microbiological Res Authority | Targetted agents for nerve regeneration |
NZ541760A (en) * | 2003-02-10 | 2008-09-26 | To Bbb Holding B V | Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions |
JP2007070225A (ja) * | 2003-07-25 | 2007-03-22 | Yukako Fujinaga | クロストリジウム属菌由来成分を含む医薬製剤 |
US8399400B2 (en) | 2004-12-01 | 2013-03-19 | Syntaxin, Ltd. | Fusion proteins |
US8603779B2 (en) | 2004-12-01 | 2013-12-10 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8778634B2 (en) | 2004-12-01 | 2014-07-15 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
US8512984B2 (en) | 2004-12-01 | 2013-08-20 | Syntaxin, Ltd. | Non-cytotoxic protein conjugates |
GB0426394D0 (en) | 2004-12-01 | 2005-01-05 | Health Prot Agency | Fusion proteins |
DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
US8343743B2 (en) | 2008-06-10 | 2013-01-01 | Synaptic Research, Llc | Designer ubiquitin ligases having a non-cleavable SNAP25 domain and E3-ligase domain |
WO2011133658A1 (en) * | 2010-04-22 | 2011-10-27 | Boston Medical Center Corporation | Compositions and methods for targeting and delivering therapeutics into cells |
US20140056870A1 (en) | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
CA2986026A1 (en) | 2015-05-15 | 2016-11-24 | Board Of Regents Of The University Of Nebraska | Engineered clostridium botulinum toxin adapted to deliver molecules into selected cells |
EP3946413A4 (en) * | 2019-04-03 | 2023-01-11 | Technical University of Denmark | NEUROTROPHIC FACTOR PROTEIN CONJUGATES AND RELATED EMBODIMENTS |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5668255A (en) * | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
WO1991009871A1 (en) * | 1989-12-22 | 1991-07-11 | Seragen Incorporated | Hybrid molecules having translocation region and cell-binding region |
US5521291A (en) * | 1991-09-30 | 1996-05-28 | Boehringer Ingelheim International, Gmbh | Conjugates for introducing nucleic acid into higher eucaryotic cells |
US5693476A (en) * | 1995-02-24 | 1997-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of screening for compounds capable of modulating vesicular release |
GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
US7192596B2 (en) * | 1996-08-23 | 2007-03-20 | The Health Protection Agency Ipsen Limited | Recombinant toxin fragments |
EP1049712B1 (en) * | 1997-08-14 | 2007-01-24 | Institut Pasteur | Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the cns |
GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
US20040071736A1 (en) * | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
GB9818548D0 (en) * | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
GB9824282D0 (en) * | 1998-11-05 | 1998-12-30 | Microbiological Research Agenc | Delivery of superoxide dismutase to neuronal cells |
CA2392208A1 (en) * | 1999-11-16 | 2001-05-25 | Johanna C. Vanderspek | Fusion proteins that specifically inhibit protein synthesis in neuronal cells |
-
2000
- 2000-12-04 ES ES00979809T patent/ES2216996T3/es not_active Expired - Lifetime
- 2000-12-04 PT PT00979809T patent/PT1234043E/pt unknown
- 2000-12-04 EP EP00979809A patent/EP1234043B1/en not_active Expired - Lifetime
- 2000-12-04 AU AU17193/01A patent/AU768529B2/en not_active Ceased
- 2000-12-04 AT AT00979809T patent/ATE261494T1/de active
- 2000-12-04 JP JP2001558083A patent/JP4991073B2/ja not_active Expired - Fee Related
- 2000-12-04 CA CA2392202A patent/CA2392202C/en not_active Expired - Fee Related
- 2000-12-04 DE DE60008915T patent/DE60008915T2/de not_active Expired - Lifetime
- 2000-12-04 WO PCT/GB2000/004644 patent/WO2001058936A2/en active IP Right Grant
- 2000-12-04 DK DK00979809T patent/DK1234043T3/da active
-
2007
- 2007-05-17 US US11/798,909 patent/US20090269361A1/en not_active Abandoned
-
2012
- 2012-02-01 US US13/363,544 patent/US20120128700A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2392202A1 (en) | 2001-08-16 |
WO2001058936A3 (en) | 2002-02-28 |
JP2003522199A (ja) | 2003-07-22 |
DE60008915D1 (de) | 2004-04-15 |
JP4991073B2 (ja) | 2012-08-01 |
ATE261494T1 (de) | 2004-03-15 |
PT1234043E (pt) | 2004-07-30 |
US20090269361A1 (en) | 2009-10-29 |
US20120128700A1 (en) | 2012-05-24 |
DE60008915T2 (de) | 2005-01-20 |
EP1234043A2 (en) | 2002-08-28 |
ES2216996T3 (es) | 2004-11-01 |
WO2001058936A2 (en) | 2001-08-16 |
EP1234043B1 (en) | 2004-03-10 |
AU1719301A (en) | 2001-08-20 |
AU768529B2 (en) | 2003-12-18 |
CA2392202C (en) | 2012-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1234043T3 (da) | Konstruktion for afgivelse af terapeutiske midler til neuroceller | |
WO2001077951A8 (en) | System and methods for group retirement plan administration | |
DK1193270T3 (da) | Pyrrolobenzodiazepiner | |
PT1280541E (pt) | Utilizacao de estirpes acetogenicas hidrogenotroficas para a prevencao ou o tratamento de disturbios digestivos | |
DK0710228T3 (da) | Hydraziner med N3S-konfiguration som radionuclidchelatorer | |
ES2183836T3 (es) | Nuevo agente para controlar la actividad celular. | |
DE59709437D1 (de) | Neue phenanthridine | |
DE69928952D1 (de) | Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe | |
ATE302005T1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
DE69435307D1 (de) | Bazillus Thuringiensis und dessen insektizide Proteine | |
CY1107637T1 (el) | Θεραπευτικη αγωγη καρκινου προστατη με αντισωματα αντι - erbb2 | |
BR9916798A (pt) | 4-arilamino, 4-arilóxi e 4-ariltio diarilaminas e seus derivados como inibidores seletivos de mek | |
PT1214936E (pt) | Utilizacao de derivados de tiazolidina ou pirrolidina de aminoacidos como agentes anti-hiperglicemicos | |
ATE302606T1 (de) | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren | |
UY26082A1 (es) | Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica | |
IT1285770B1 (it) | Composti corticoidei | |
WO2000032196A3 (en) | Inhibitors of multidrug transporters | |
ATE405294T1 (de) | Gezielt eingesetzte agenzien zur nervenregeneration | |
ATE203519T1 (de) | Chinolinderivate als antimalariamittel | |
DK0946157T3 (da) | Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte | |
TR199802351T2 (xx) | Topikal kullanım için bir veya birden fazla lokal anestezik ve anti-vajinit maddeler ihtiva eden anti-vajinit bileşimi. | |
NZ336781A (en) | Fibronectin binding protein compositions, antibodies thereto, and methods of use | |
DE69735479D1 (de) | Metalloproteinase inhibitoren | |
BR0009101A (pt) | 9a-azalidas com atividade antibacteriana | |
BR9814188A (pt) | "agonistas de 5-ht1f" |